Key result
Preconditioning ADSCs with platelet extracellular vesicles enhances proangiogenic potential and improves perfusion in murine ischemia.
Why the study?
ADSC-based therapy for ischaemic disease is limited by poor paracrine function and low survival, prompting investigation into whether platelet extracellular vesicles can modulate the proangiogenic potential of ADSCs.
Does treatment with platelet extracellular vesicles enhance the proangiogenic potential of adipose-derived stem cells in mouse hindlimb ischaemia models?
Does treatment with platelet extracellular vesicles enhance the proangiogenic potential of adipose-derived stem cells in mouse hindlimb ischaemia models?
p-value: p=<0.05
Preconditioning adipose-derived stem cells with platelet extracellular vesicles enhances their proangiogenic and therapeutic potential in ischemic disease models.
Should not change clinical practice in ischemia; leaves open translation of vesicle-preconditioned stem cells to human trials.
BACKGROUND: Adipose-derived mesenchymal stem cells (ADSC)-based therapy is an outstanding treatment strategy for ischaemic disease. However, the therapeutic efficacy of this strategy is not ideal due to the poor paracrine function and low survival rate of ADSCs in target regions. Platelet extracellular vesicles (PEVs) are nanoparticles derived from activated platelets that can participate in communication between cells. Accumulating evidence indicates that PEVs can regulate the biological functions of several cell lines. In the present study, we aimed to investigate whether PEVs can modulate the proangiogenic potential of ADSCs in vitro and in vivo. METHODS: -induced hypoxia condition. The underlying mechanisms by which PEVs affected ADSCs were explored using real time-PCR(RT-PCR) and Western blot. In addition, matrigel plug assays were conducted and mouse hindlimb ischaemic models were established to investigate the proangiogenic potential of PEV-treated ADSCs in vivo. RESULTS: We demonstrated that ADSC could internalize PEVs, which lead to a series of biological reactions. In vitro, dose-dependent effects of PEVs on ADSC proliferation, migration and antiapoptotic capacity were observed. Western blotting results suggested that multiple proteins such as ERK, AKT, FAK, Src and PLCγ1 kinase may contribute to these changes. Furthermore, PEVs induced upregulation of several growth factors expression in ADSCs and amplified the proliferation, migration and tube formation of HUVECs induced by ADSC conditioned medium (CM). In in vivo experiments, compared with control ADSCs, the injection of PEV-treated ADSCs resulted in more vascularization in matrigel plugs, attenuated tissue degeneration and increased blood flow and capillary density in ischaemic hindlimb tissues. CONCLUSION: Our data demonstrated that PEVs could enhance the proangiogenic potential of ADSCs in mouse hindlimb ischaemia. The major mechanisms of this effect included the promotion of ADSC proliferation, migration, anti-apoptosis ability and paracrine secretion.
No takes yet. Share an insight, caveat, or question.
Tang et al. (2021) studied Hindlimb ischemia (n=30). Platelet extracellular vesicles (PEVs) preconditioning of ADSCs vs. ADSCs treated with PBS was evaluated on Blood perfusion recovery and capillary density in ischemic hindlimb (p=<0.05). Preconditioning adipose-derived stem cells with platelet extracellular vesicles significantly enhanced their proangiogenic potential, improving blood perfusion recovery in a mouse hindlimb ischemia model.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: